C.GuedesG
Key Points Despite the broad biological and clinical heterogeneity of systemic lupus erythematosus (SLE), specific pathways of immune dysregulation have been well characterized and are known to be relevant to significant subsets of patients Selective targeting of key immune regulatory molecules seems to offer promise for effective disease management with lower toxicity than current therapies Selection of patients that are likely to respond to a particular therapeutic agent could eventually be guided by biomarkers predictive and reflective of response to that treatment Clinical trials of biologic agents in SLE are significantly confounded by aggressive use of background medications that decrease the ability to detect differences between the study and control groups In patients with mild disease manifestations, withdrawal of background medications might allow the implementation of smaller, true placebo-controlled clinical trials In patients with high baseline disease activity, withdrawal of background therapies might not be feasible, but these individuals tend to have less profound responses on background therapies, and therefore trials limited to these patients can succeed without withdrawal of these agents Abstract Despite rapid accumulation of knowledge about complex immune dysregulation in systemic lupus erythematosus (SLE) and major primary lupus syndromes, and a plethora of promising new treatments reaching preclinical and early clinical studies, advanced-phase trials of new biologic agents have repeatedly failed to achieve their clinical end points
The injectable form provides systemic effects while topical application targets specific areas directly
Gaskins AJ, Sundaram R, Buck Louis GM, Chavarro JE
Furthermore, we suggested different potential drugs, such as Doxorubicin and LIN001-260, to target multiple hub genes
